© 2022 MJH Life Sciences™ and Center for Biosimilars®. All rights reserved.
Not So Different: What’s Stopping Physicians From Prescribing Biosimilars?
This is the second of a 3-part series on National Comprehensive Cancer Network/Pfizer efforts to investigate issues of importance to biosimilar stakeholders.
In March 2021, the National Comprehensive Cancer Network’s (NCCN) Oncology Research Program, in partnership with Pfizer, announced 10 research projects that will receive funding to develop innovative ways to improve biosimilar adoption in the oncology space.
For this Not So Different series, The Center for Biosimilars® is spotlighting 3 projects to improve perception of biosimilars, promote biosimilars as a therapy choice, and encourage payers to prefer biosimilar use.
In this second part, we spoke with Muhammad Shaalan Beg, MD, director of GI Medical Oncology at UT Southwestern Medical Center. Dr Beg discussed how his project titled “Developing a Clinical Decision Support Tool for Biosimilar Use in Oncology” will make it easier for physicians to choose biosimilars for their patients.
To learn more about struggles regarding physician decisions on biosimilars, click here.
For more on payer influence on prescribing patterns, click here.
For more on NCCN’s biosimilar work, click here.
